Group 1 - The Chinese Ministry of Foreign Affairs noted the U.S. decision to allow NVIDIA to sell H200 AI chips to approved customers in China, emphasizing the importance of cooperation for mutual benefit between China and the U.S. [1] - The Chinese Ministry of Commerce highlighted the retail sector as a key focus for developing a complete domestic demand system and promoting high-quality development during the 14th Five-Year Plan period [1] - A new multi-crystalline silicon capacity integration acquisition platform named Beijing Guanghe Qiancheng Technology Co., Ltd. has been established with a registered capital of 3 billion, aimed at exploring strategic cooperation opportunities within the industry [1] Group 2 - The Ministry of Agriculture and Rural Affairs reported that pork supply in November was sufficient, with prices slightly decreasing. The number of breeding sows fell to 39.9 million, marking a 1.1% month-on-month decrease and a 2.1% year-on-year decrease [2] - The Quanzhou Municipal Committee proposed initiatives to enhance infrastructure connectivity with Taiwan, including improving transportation and utilities, and supporting Taiwanese residents in various aspects of life in Quanzhou [2] Group 3 - The draft measures to promote the sales of liquor in Guizhou include supporting collaboration between liquor companies and financial institutions, exploring new financial products, and ensuring product quality while combating market violations [3]

Group 1 - The company held its 8th meeting of the 2nd Board of Directors on December 8, 2025, to discuss the issuance of H-shares and listing on the Hong Kong Stock Exchange [2][3][31] - The board unanimously approved the proposal to issue H-shares and apply for listing on the Hong Kong Stock Exchange [4][8][31] Group 2 - The H-shares will be ordinary shares with a nominal value of RMB 1.00, issued in foreign currency [7] - The listing will take place on the main board of the Hong Kong Stock Exchange, with the timing to be determined based on market conditions and regulatory approvals [10][12] - The issuance will include both a public offering in Hong Kong and an international placement [12][20] Group 3 - The maximum number of H-shares to be issued will not exceed 25% of the total share capital post-issuance, with an option for an additional 15% for over-allotment [14] - The pricing of the shares will be determined based on market conditions and investor demand [16] - The target investors include qualified international institutional investors and eligible domestic investors [18] Group 4 - The funds raised from the H-share issuance will be used for clinical development of core research pipelines, preclinical exploration, and general corporate purposes [33][34] - The board proposed to authorize the board and its authorized persons to handle all matters related to the issuance and listing of H-shares [35][50] Group 5 - The company will apply to register as a non-Hong Kong company in accordance with Hong Kong laws for the purpose of the H-share listing [52] - The board approved a profit distribution plan for retained earnings prior to the H-share issuance, ensuring that both existing and future shareholders share in the profits [54] Group 6 - The board agreed to draft a new set of articles of association applicable after the H-share issuance, in compliance with relevant laws and regulations [58][60] - The internal governance rules will be revised to align with the requirements of the H-share listing [63][65]

Group 1 - Rhein Biotech and Jia Mei Packaging's controlling shareholders are planning changes in company control, with trading suspension starting from December 10, 2025, for Rhein Biotech expected to last no more than 10 trading days and for Jia Mei Packaging no more than 2 trading days [1][2] - Rhein Biotech intends to acquire at least 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a combination of issuing shares and cash payment, which will make Beijing Jinkangpu a subsidiary included in the consolidated financial statements [1] - Jia Mei Packaging's controlling shareholder is also in discussions regarding a potential change in control, with specific transaction details still under negotiation [2] Group 2 - Haiguang Information has terminated its plan to merge with Zhongke Shuguang through a share exchange, as approved in a board meeting on December 9, 2025 [3] - Huatai Medical plans to repurchase shares with a total amount not less than RMB 200 million and not exceeding RMB 250 million, with a repurchase price cap of RMB 315 per share [4] - Songcheng Performing Arts and Jingu Co., Ltd. also announced share repurchase plans, with Songcheng aiming for a total of RMB 100 million to RMB 200 million and Jingu targeting RMB 30 million to RMB 60 million [4] Group 3 - Xiamen Airport is planning to acquire 100% of the shares of Zhaoxiang Technology, a wholly-owned subsidiary of its controlling shareholder, Xiamen Xiangye Group [5] - Borui Communication intends to acquire 51% of Meijing Technology from related parties for a total price of RMB 66.49 million [6] - Gu Ao Technology's actual controller is planning a change in control, with trading suspension starting from December 8, 2025, and expected to last no more than 3 trading days [6] Group 4 - ST Kevin's application to revoke the risk warning on its stock has been approved, with trading suspension for one day on December 10, 2025, and resuming trading on December 11, 2025 [6] - Huailun Crystal's stock will be suspended for one day starting December 10, 2025, due to false disclosures in its annual reports for 2021 and 2022 [7] - The stock of Jia Ao Environmental Protection will also be suspended for one day on December 10, 2025, due to an administrative penalty notice received from the regulatory authority [12] Group 5 - The company Yongmota plans to invest approximately RMB 400 million in a new project for magnesium-aluminum alloy components for the automotive and robotics industries [20] - ST Ningke is executing a capital reserve transfer plan to increase its share capital, with a total share increase from 684.88 million to 1.62 billion shares [21] - Yingpais plans to increase its shareholding through a combination of bank loans and self-funding, with a total investment of no less than RMB 60 million and no more than RMB 120 million [22]

益方生物(688382.SH)发布公告，为进一步提高公司的资本实力和综合竞争力，深入推进公司发展战 略，更好利用国际资本市场的多元化融资渠道，公司拟于境外发行股份(H股)，并申请在香港联合交易 所有限公司主板挂牌上市。 ...

本文源自：智通财经网 智通财经讯，益方生物(688382.SH)发布公告，为进一步提高公司的资本实力和综合竞争力，深入推进 公司发展战略，更好利用国际资本市场的多元化融资渠道，公司拟于境外发行股份(H股)，并申请在香 港联合交易所有限公司主板挂牌上市。 ...

益方生物表示，截至目前，公司正与相关中介机构就本次发行上市的相关工作进行商讨，除本次董事会 审议通过的相关议案外，其他关于本次发行上市的具体细节尚未最终确定。本次发行H股并上市事项尚 需提交公司股东会审议。 北京商报讯（记者 丁宁）12月9日晚间，益方生物（688382）发布公告称，为进一步提高公司的资本实 力和综合竞争力，深入推进公司发展战略，更好利用国际资本市场的多元化融资渠道，公司拟于境外发 行股份（H股），并申请在香港联交所主板挂牌上市。 ...

Group 1 - The core viewpoint of the article highlights the recent developments in Yifang Biotechnology, including the announcement of its board meeting and the company's financial performance in the pharmaceutical manufacturing sector [1] - Yifang Biotechnology's revenue composition for the year 2024 is reported to be 100% from the pharmaceutical manufacturing industry [1] - As of the report, Yifang Biotechnology has a market capitalization of 16.3 billion yuan [1] Group 2 - The article also discusses a concerning trend in the pharmaceutical industry, specifically the abuse of pregabalin leading to addiction cases, marking the first report of such incidents in the domestic market [1] - It mentions vulnerabilities in online platforms that allow the purchase of medications without proper medical records, raising questions about regulatory oversight [1] - The classification of pregabalin and the need for scientific evaluation regarding its regulation are emphasized as critical issues [1]

第一章 总则 益方生物科技（上海）股份有限公司 章 程 （草案） （H 股发行并上市后适用） | 第一章 | 总则 - | 1 | - | | --- | --- | --- | --- | | 第二章 | 经营宗旨和范围 - | 2 | - | | 第三章 | 股份 - | 3 | - | | 第一节 | 股份发行 | - 3 | - | | 第二节 | 股份增减和回购 | - 5 | - | | 第三节 | 股份转让 | - 7 | - | | 第四章 | 股东和股东会 - | 8 | - | | 第一节 | 股东 | - 8 | - | | 第二节 | 股东会的一般规定 - | 12 | - | | 第三节 | 股东会的召集 - | 15 | - | | 第四节 | 股东会的提案与通知 - | 17 | - | | 第五节 | 股东会的召开 - | 18 | - | | 第六节 | 股东会的表决和决议 - | 22 | - | | 第五章 | 董事会 - | 25 | - | | 第一节 | 董事 - | 25 | - | | 第二节 | 独立董事 - | 29 | - | | 第三节 | 董事会 - ...

（草案） （H 股发行并上市后适用） 1 益方生物科技（上海）股份有限公司 股东会议事规则 第一章 总则 第一条 为了进一步规范益方生物科技（上海）股份有限公司（下称"公司"） 行为，保障公司股东会能够依法行使职权，根据《中华人民共和国公司法》（下 称"《公司法》"）、《中华人民共和国证券法》（下称"《证券法》"）、《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》、《上市公司股东 会规则》、《境内企业境外发行证券和上市管理试行办法》、《香港联合交易所有限 公司证券上市规则》（以下简称"《香港上市规则》"）等有关法律、法规、规范性 文件和《益方生物科技（上海）股份有限公司章程》（下称"《公司章程》"）等 规定，制订本益方生物科技（上海）股份有限公司股东会议事规则（下称"本议 事规则"）。 第二条 本议事规则适用于公司股东会，对公司、全体股东、股东代理人、 公司董事、总经理及其他高级管理人员和列席股东会会议的其他有关人员均具有 约束力。 第三条 公司董事会应严格遵守相关法规关于召开股东会的各项规定，认真 按时组织好股东会。公司全体董事对股东会的正常召开负有诚信责任，公司董事 会应当切实履行职责 ...

独立董事工作制度 益方生物科技（上海）股份有限公司 （草案） （H 股发行并上市后适用） 第一章 总则 第一条 为完善益方生物科技（上海）股份有限公司（下称"公司"）治理 结构，促进公司规范运作，维护公司和股东的利益，根据《中华人民共和国公司 法》《上市公司独立董事管理办法》（下称"《管理办法》"）、《香港联合交 易所有限公司证券上市规则》（下称"《香港上市规则》"）以及《益方生物科 技（上海）股份有限公司章程》（下称"《公司章程》"）的有关规定，并结合 公司实际情况，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主 要股东不存在直接或者间接利害关系，或者其他可能影响其进行独立客观判断关 系的董事。本制度中"独立董事"的含义与《香港上市规则》中"独立非执行董 事"的含义一致，独立董事须同时符合《香港上市规则》要求的独立性。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务。独立董事应当按 照有关法律、行政法规、规范性文件、公司股票上市地证券监管规则和《公司章 程》的要求，认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询作 用，维护公司整体利益，保护中小股东合法权益。 ...